Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies

Zachary A. Hing(The Ohio State University), Rosa Lapalombella(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Shaneice Mitchell(Stanford University), Jordan L. Smith(University of Massachusetts Chan Medical School), Virginia M. Goettl(The Ohio State University), Katie Williams(The Ohio State University), Qingxiang Sun(University of Electronic Science and Technology of China), Sharon Shacham(Roche (Switzerland)), Yuh Min Chook(The University of Texas Southwestern Medical Center), Ramiro Garzon(Unknown), Erkan Baloglu(ProterixBio (United States)), Tolga Çağatay(The University of Texas Southwestern Medical Center), Parvathi Ranganathan(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), John B. MacMillan(The University of Texas Southwestern Medical Center), Ho Yee Joyce Fung(Southwestern Medical Center), Dalia El‐Gamal(University of Nebraska Medical Center), Xueyan Yu(Shaanxi Provincial People's Hospital), David Lucas(Vital Strategies), Amy M. Lehman(The Ohio State University), Michael Kauffman(Roche (Switzerland)), John C. Byrd(University of Cincinnati), Xiaomei Meng(Hebei General Hospital), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute)
Blood
December 3, 2015
Cited by 1


Related Papers